Skip to main content

Table 1 Sociodemographic and clinical data of participants owning a smartphone and non-participants

From: Mobile App-based documentation of patient-reported outcomes — 3-months results from a proof-of-concept study on modern rheumatology patient management

 

Non-participants

(n = 208)

MiDEAR participants

BL

(n = 60)

MiDEAR participant

follow-up

(N = 51)

NDB

(n = 8481)

Age (mean (SD)) years

61.2 (14.8)

50.1 (13.1)*

49.1 (12.3)*

62.6 (14.0)

Female ((%))

150 (72.1)

47 (78.3)*

40 (78.4)*

6369 (75.1)

Disease duration (mean (SD)) years

10.0 (10.1)

10.5 (9.1)*

10.5 (9.7)*

13.3 (10.3)

DAS28 (mean (SD)) baseline

2.7 (1.1)

2.6 (1.0)*

2.6 (1.0)*

2.8 (1.0)

DAS28 (mean (SD)) follow-up

n.a.

n.app.

2.5 (0.8)

n.a.

HAQ (mean (SD))

(Paper-based for MIDEAR participants)

1.21 (0.71)

0.78 (0.59)*

0.69 (0.50)*

0.88 (0.69)

HAQ (mean (SD)) follow-up (Paper-based for MIDEAR participants)

n.a.

n.app.

0.69 (0.50)

n.a.

Number of co-morbidities (median (IQR))

2 (1.0–3.0)

2 (1.0–3.8)*

2 (0–3.0) *

2 (1.0–4.0)

Education: University entrance diploma (n (%))

59 (28.4)

30 (50.0)*

28 (54.9)*

1120 (24.4)

Medication

 NSAIDs (n (%))

85 (40.9)

28 (46.7)

24 (47.1)

2782 (48.6)

 Glucocorticoids (n (%))

121 (58.2)

30 (50.0)

26 (51.0)

2717 (47.5)

 csDMARDs alone (n (%))

115 (55.3)

36 (60.0)

30 (58.8)

3485 (61.1)

 Biological DMARD either alone or in combination with csDMARD (n (%))

67 (32.2)

20 (33.3)

17 (33.3)

1576 (27.6)

  1. n.a. not available, n.app. not applicable, *values refer to baseline assessments, BL baseline, NDB national database